326.28  5.93 (1.85%)		11-11 16:00
Open: 321.96 High: 327.38 Volume: 476,617		Pre. Close: 320.35 Low: 321.96 Market Cap: 22,953(M)

Short term
Mid term
Targets	6-month :	391.58	1-year :	457.36
Resists	First :	335.26	Second :	391.58
Pivot price	320.54
Supports	First :	307.38	Second :	290.16
MAs	MA(5) :	320.84	MA(20) :	320.56
	MA(100) :	314.6	MA(250) :	291.07
MACD	MACD :	0.1	Signal :	-0.6
%K %D	K(14,3) :	70.8	D(3) :	64.4
RSI	RSI(14): 55.4
52-week	High :	353.5	Low :	230.05

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PODD ] has closed below upper band by 20.9%. Bollinger Bands are 36.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	327.81 - 329.13	329.13 - 330.39
Low:	318.64 - 320.12	320.12 - 321.53
Close:	323.87 - 326.18	326.18 - 328.38

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Mon, 10 Nov 2025
Insulet (PODD) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance

Sun, 09 Nov 2025
Insulet Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - simplywall.st

Fri, 07 Nov 2025
Insulet Corporation (NASDAQ:PODD) Q3 2025 Earnings Call Transcript - Insider Monkey

Fri, 07 Nov 2025
Jefferies Maintains Insulet (PODD) Buy Recommendation - Nasdaq

Fri, 07 Nov 2025
How Insulet’s (PODD) Raised Outlook and Surging Omnipod Demand Will Impact Investors - simplywall.st

Thu, 06 Nov 2025
Insulet Corp. Reveals Advance In Q3 Income - Nasdaq

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	70 (M)
Shares Float	70 (M)
Held by Insiders	0.2 (%)
Held by Institutions	102.1 (%)
Shares Short	1,610 (K)
Shares Short P.Month	1,500 (K)

EPS	3.26
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	20.78
Profit Margin	10 %
Operating Margin	18.6 %
Return on Assets (ttm)	7.7 %
Return on Equity (ttm)	19.1 %
Qtrly Rev. Growth	32.9 %
Gross Profit (p.s.)	23.58
Sales Per Share	33.52
EBITDA (p.s.)	6.82
Qtrly Earnings Growth	-87.7 %
Operating Cash Flow	516 (M)
Levered Free Cash Flow	113 (M)

PE Ratio	99.76
PEG Ratio	0
Price to Book value	15.69
Price to Sales	9.73
Price to Cash Flow	44.48

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.